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Introduction
Vasomotor symptoms such as hotflushes and night
sweats, associated with insomnia and cognitive
dysfunction, commonly occur in women after the
menopause and are caused by a lowering of oestrogen
levels in the hypothalamus due to ovarian failure. These
symptoms are the main reason for women taking
oestrogen (sometimes with a progestin) as hormone
replacement therapy (HRT). An added advantage of taking
oestrogen is that it also prevents bone loss and
osteoporotic fractures. However, HRT has been
associated with an increase in breast cancer, uterine
cancer, thromboembolism, heart disease and stroke [1]. 
Because of these problems, there is now a substantial
effort to develop drugs with a spectrum of oestrogenic
and anti-oestrogenic activity (the Selective Estrogenic
Receptor Modulators or SERMS), which give a better
profile of activity than oestrogen for women’s health
benefits. For example, the SERM raloxifene (Evista, Eli
Lilly) has been shown to reduce the risk of breast cancer
[2], osteoporotic fractures in the spine [3], and heart
disease in women at high risk [4], but it is not effective at
reducing vasomotor and cognitive symptoms and, like
oestrogen, still causes an increase in thromboembolism.
The search therefore continues to find the ideal SERM
that has a spectrum of oestrogenic and antioestrogenic
activity which would reduce vasomotor symptoms,
improve cognitive dysfunction, reduce breast cancer,
uterine cancer and perhaps ovarian cancer, reduce the
risk of osteoporotic fracture, heart disease and stroke, and
not cause an increase in thromboembolism. This is
theoretically possible.
Natural products and women’s health
For many years plant extracts have been used for
controlling the vasomotor symptoms of the menopause,
which would indicate that there are naturally occurring
phytoestrogenic agents in these plants [5]. A group of
candidate agents likely to be oestrogenically active in
these plant extracts are the isoflavones. The question is
then raised as to whether these extracts, used to control
vasomotor symptoms, have adverse effects like HRT, and
if they increase breast cancer risk. There is good
epidemiological evidence, however, that in Asian
populations where the diet is high in isoflavones, from
sources such as soya [6] there is a low incidence of
breast cancer, osteoporosis, heart disease and stroke with
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Abstract
There is evidence that diets which contain high levels of phytoestrogenic isoflavanoids are associated
with a low incidence of osteoporosis and menopausal vasomotor symptoms. Plant extracts such as red
clover, which contain high levels of isoflavanoids, have been used to reduce menopausal symptoms
and have been shown to reduce bone loss in healthy women. A placebo-controlled clinical trial
[ISRCTN42940165] of red clover is reported in this issue of Breast Cancer Research and shows that
these phytoestrogens do not cause any oestrogenic increase in breast density, which would indicate
that they are unlikely to cause an increased risk of breast cancer.
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no evidence of an increase in thromboembolism. It is
therefore possible that some of these agents may have an
ideal SERM spectrum of activity. This justifies rigorous
testing in clinical trials in order to establish that these
natural products, which are easily available and widely
used to alleviate hot flushes, are not oestrogenic on the
breast and not likely to increase breast cancer risk.
One of the main problems with assessing natural products
for health benefits is the lack of good clinical trial data.
Most of the evidence is, at best, anecdotal involving the
uncontrolled use of products of unknown quality. There is
no doubt that many of these traditional ‘medicines’ are
biologically active and by a process of natural selection
may be beneficial. However, like pharmaceutical products,
the beneficial effects are likely to be dose dependent and
it is likely that these active agents would have a spectrum
of biological activity that may cause toxicity. Without good
clinical trial data and with no quality control of the product
it is unlikely these agents would consistently provide
therapeutic benefit.
It therefore makes sense that if there are good reasons to
suppose that a natural product may have a therapeutic
benefit in humans (i.e. there is a reasonable hypothesis to
be tested) it should be tested according to the strict
scientific methodology of clinical research. This means
that the product, usually an extract of a plant, should be of
known quality and quantity so the exact amounts of the
known constituents are reproducibly present in the
medication. (This usually means quality assurance by gas
liquid chromatography and mass spectrometry of all
preparations). The product then needs to be tested by the
established methodology of clinical research in order to
provide reliable results. This will usually require double
blind placebo controlled clinical trials with clearly defined
outcomes and adequate statistical power. Potential
toxicity needs to be carefully evaluated. Only then is it
possible to evaluate the overall value of use of the product
as a medication for humans.
Red clover isoflavone trials
On this basis, the paper in this issue of the journal, by
Atkinson and colleagues, [7] reports a randomised, double-
blind, placebo-controlled trial of Promensil (Novogen), an
extract of red clover, given to 205 pre- and postmeno-
pausal healthy women with radiologically dense breasts
(an established oestrogenic risk factor for breast cancer).
Promensil is an extract of red clover containing very
accurately determined amounts of the principal isoflava-
noids: biochanin A, formononetin, genistein and daidzein
(total isoflavanoid content of 40 mg per tablet) [8]. The
trial is well designed with the principal objective of
evaluating any adverse oestrogenic effect of red clover, at
a dose of 40 mg of isoflavones per day, on breast density
as a surrogate marker of increased breast cancer risk.
The study has shown that, at this dose of Promensil, there
is no evidence of any increase in radiological breast
density in women who already have increased breast
density, in spite of the well-documented evidence that
HRT will increase breast density and tamoxifen will reduce
breast density. There is little other data relating to
isoflavones and breast density, with only one small trial
involving 30 premenopausal women receiving 100 mg of
isoflavones versus placebo for one year showing no
significant effect on breast density [9]. Larger trials are
needed to evaluate the effect of these higher doses of
isoflavones on healthy women particularly those with an
increased breast density.
Rather surprisingly, the trial reported by Atkinson and
colleagues failed to show any beneficial effect on
menopausal symptoms or reduction in follicle-stimulating
hormone in post menopausal women, indicating a lack of
oestrogenic activity of 40 mg per day of Promensil on the
hypothalamus. A recent small but well designed trial
reported by van de Weijer showed that 12 weeks of
80 mg per day of Promensil in 30 healthy women with
marked vasomotor symptoms caused a 44% reduction in
hot flushes for women on Promensil compared to placebo
(P < 0.01) [10]. The negative result in the trial reported by
Atkinson and colleagues may be because women in the
trial women were not recruited because of moderate or
marked hot flushes and the dose of Promensil was only
40 mg per day.
In this same trial, a recent paper reports the results of
bone density and bone marker measurements in the 205
women [11]. The results shows that Promensil will
significantly reduce the loss of bone mineral density in the
lumber spine compared to placebo (P < 0.05), with an
associated increase in markers of bone formation
(P < 0.05) indicating a beneficial oestrogenic effect of
40 mg per day of isoflavones for one year on the bones.
Conclusion
Overall, this trial has shown encouraging evidence of a
significant oestrogenic effect of 40 mg of isoflavanoids on
bone with no evidence of an adverse oestrogenic effect
on breast density. The possible benefit on vasomotor
symptoms has not been adequately tested in this trial.
Larger trials, involving more women treated for a longer
period and perhaps at higher doses, are needed to test for
possible overall clinical benefit in healthy women. At this
time it is reassuring that there is no evidences that the
widespread use of isoflavones to treat hot flushes is likely
to be harmful.
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